Gap junction diseases of the skin: Novel insights from new mutations

Expert Review of Dermatology

Volumn 4, Issue 5, 2009, Pages 455-468

  De Zwart Storm, Eugene A ^a   Martin, Patricia E ^b   Van Steensel, Maurice A M ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Connexins; Cx26; Gap junction; GJA1; GJB2; GJB3; GJB4; GJB6

Indexed keywords

CONNEXIN 26; CONNEXIN 30; CONNEXIN 30.3; CONNEXIN 31; CONNEXIN 43; GAP JUNCTION PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; BART PUMPHREY SYNDROME; ERYTHROKERATODERMA FIGURATA VARIABILIS; GAP JUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HIDROTIC ECTODERMAL DYSPLASIA; HUMAN; HYPOTRICHOSIS DEAFNESS SYNDROME; INFECTION RISK; KERATODERMA HEREDITARIUM MUTILANS; MUCOSITIS DEAFNESS SYNDROME; NONHUMAN; OCULODENTODIGITAL SYNDROME; PALMOPLANTAR KERATODERMA; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SYNDROME KID;

EID: 70350637544     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.09.47     Document Type: Review

References (123)

1. Yen MR, Saier MH Jr. Gap junctional proteins of animals: the innexin/pannexin superfamily. Prog. Biophys. Mol. Biol. 94(1-2), 5-14 (2007).
2. Barbe MT, Monyer H, Bruzzone R. Cell-cell communication beyond connexins: the pannexin channels. Physiology (Bethesda USA) 21, 103-114 (2006).
3. Yahalom A, Warmbrodt RD, Laird DW et al. Maize mesocotyl plasmodesmata proteins cross-react with connexin gap junction protein antibodies. Plant Cell 3(4), 407-417 (1991). (Pubitemid 21913707)
4. Dahl G, Locovei S. Pannexin: to gap or not to gap, is that a question? IUBMB Life 58(7), 409-419 (2006). (Pubitemid 43995626)
5. Penuela S, Bhalla R, Gong XQ et al. Pannexin 1 and pannexin 3 are glycoproteins that exhibit many distinct characteristics from the connexin family of gap junction proteins. J. Cell. Sci. 120(Pt 21), 3772-3783 (2007). (Pubitemid 350187359)
6. Evans WH, Martin PE. Gap junctions: structure and function (review). Mol. Membr. Biol. 19(2), 121-136 (2002).
7. 2+ in gap-junction remodeling: studies in humans and rats. Naunyn Schmiedebergs Arch. Pharmacol. 377(2), 125-138 (2008).
8. Wang X, Li L, Peracchia LL, Peracchia C. Chimeric evidence for a role of the connexin cytoplasmic loop in gap junction channel gating. Pflugers Arch. 431(6), 844-852 (1996).
9. Mese G, Richard G, White TW. Gap junctions: basic structure and function. J. Invest. Dermatol. 127(11), 2516-2524 (2007). (Pubitemid 47585051)
10. Maeda S, Nakagawa S, Suga M et al. Structure of the connexin 26 gap junction channel at 3.5 A resolution. Nature 458(7238), 597-602 (2009).
11. De Vuyst E, Decrock E, Cabooter L et al. Intracellular calcium changes trigger connexin 32 hemichannel opening. Embo. J. 25(1), 34-44 (2006). (Pubitemid 43077293)
12. Evans WH, De Vuyst E, Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem. J. 397(1), 1-14 (2006). (Pubitemid 44032830)
13. Laird DW. Life cycle of connexins in health and disease. Biochem. J. 394(Pt 3), 527-543 (2006).
14. Salomon D, Masgrau E, Vischer S et al. Topography of mammalian connexins in human skin. J. Invest. Dermatol. 103(2), 240-247 (1994). (Pubitemid 24234615)
15. Wiszniewski L, Limat A, Saurat JH, Meda P, Salomon D. Differential expression of connexins during stratification of human keratinocytes. J. Invest. Dermatol. 115(2), 278-285 (2000). (Pubitemid 30637199)
16. Kretz M, Euwens C, Hombach S et al. Altered connexin expression and wound healing in the epidermis of connexin-deficient mice. J. Cell. Sci. 116(Pt 16), 3443-3452 (2003). (Pubitemid 37038991)
17. Goliger JA, Paul DL. Expression of gap junction proteins Cx26, Cx31.1, Cx37, and Cx43 in developing and mature rat epidermis. Dev. Dyn. 200(1), 1-13 (1994).
18. Di WL, Gu Y, Common JE et al. Connexin interaction patterns in keratinocytes revealed morphologically and by FRET analysis. J. Cell. Sci. 118(Pt 7), 1505-1514 (2005).
19. Duffy HS, Fort AG, Spray DC. Cardiac connexins: genes to nexus. Adv. Cardiol. 42, 1-17 (2006).
20. Koval M. Pathways and control of connexin oligomerization. Trends Cell. Biol. 16(3), 159-166 (2006).
21. Martin PE, Blundell G, Ahmad S, Errington RJ, Evans WH. Multiple pathways in the trafficking and assembly of connexin 26, 32 and 43 into gap junction intercellular communication channels. J. Cell. Sci. 114(Pt 21), 3845-3855 (2001). (Pubitemid 33094699)
22. Martin PE, Errington RJ, Evans WH. Gap junction assembly: multiple connexin fluorophores identify complex trafficking pathways. Cell. Commun. Adhes. 8(4-6), 243-248 (2001).
23. Das S, Smith TD, Sarma JD et al. ERp29 restricts Connexin43 oligomerization in the endoplasmic reticulum. Mol. Biol. Cell. 20(10), 2593-2604 (2009).
24. Oshima A, Tani K, Hiroaki Y, Fujiyoshi Y, Sosinsky GE. Three-dimensional structure of a human connexin26 gap junction channel reveals a plug in the vestibule. Proc. Natl Acad. Sci. USA 104(24), 10034-10039 (2007).
25. Tao L, Harris AL. 2-aminoethoxydiphenyl borate directly inhibits channels composed of connexin26 and/or connexin 32. Mol. Pharmacol. 71(2), 570-579 (2007). (Pubitemid 46147921)
26. Delmar M, Coombs W, Sorgen P, Duffy HS, Taffet SM. Structural bases for the chemical regulation of Connexin 43 channels. Cardiovasc. Res. 62(2), 268-275 (2004). (Pubitemid 38496540)
27. Henzl MT, Thalmann I, Larson JD, Ignatova EG, Thalmann R. The cochlear F-box protein OCP1 associates with OCP2 and connexin 26. Hear Res. 191(1-2), 101-109 (2004). (Pubitemid 38510515)
28. Rahman S, Evans WH. Topography of connexin32 in rat liver gap junctions. Evidence for an intramolecular disulphide linkage connecting the two extracellular peptide loops. J. Cell. Sci. 100(Pt 3), 567-578 (1991).
29. Zhou Y, Yang W, Lurtz MM et al. Identification of the calmodulin binding domain of connexin43. J. Biol. Chem. 282(48), 35005-35017 (2007). (Pubitemid 350232453)
30. Gomez-Hernandez JM, de Miguel M, Larrosa B, Gonzalez D, Barrio LC. Molecular basis of calcium regulation in connexin-32 hemichannels. Proc. Natl Acad. Sci. USA 100(26), 16030-16035 (2003). (Pubitemid 38021109)
31. de Zwart-Storm EA, van Geel M, van Neer PA, Steijlen PM, Martin PE, van Steensel MA. A novel missense mutation in the second extracellular domain of GJB2, p.Ser183Phe, causes a syndrome of focal palmoplantar keratoderma with deafness. Am. J. Pathol. 173(4), 1113-1119 (2008).
32. Marziano NK, Casalotti SO, Portelli AE, Becker DL, Forge A. Mutations in the gene for connexin 26 (GJB2) that cause hearing loss have a dominant negative effect on connexin 30. Hum. Mol. Genet. 12(8), 805-812 (2003). (Pubitemid 36504023)
33. Thomas T, Telford D, Laird DW. Functional domain mapping and selective trans-dominant effects exhibited by Cx26 disease-causing mutations. J. Biol. Chem. 279(18), 19157-19168 (2004). (Pubitemid 38623347)
34. He LQ, Liu Y, Cai F et al. Intracellular distribution, assembly and effect of disease-associated connexin 31 mutants in HeLa cells. Acta Biochim. Biophys. Sin. (Shanghai) 37(8), 547-554 (2005). (Pubitemid 41608068)
35. Di WL, Monypenny J, Common JE et al. Defective trafficking and cell death is characteristic of skin disease-associated connexin 31 mutations. Hum. Mol. Genet. 11(17), 2005-2014 (2002).
36. Stong BC, Chang Q, Ahmad S, Lin X. A novel mechanism for connexin 26 mutation linked deafness: cell death caused by leaky gap junction hemichannels. Laryngoscope 116(12), 2205-2210 (2006). (Pubitemid 44912318)
37. Gerido DA, DeRosa AM, Richard G, White TW. Aberrant hemichannel properties of Cx26 mutations causing skin disease and deafness. Am. J. Physiol. Cell. Physiol. 293(1), C337-C345 (2007).
38. Matos TD, Caria H, Simoes-Teixeira H et al. A novel M163L mutation in connexin 26 causing cell death and associated with autosomal dominant hearing loss. Hear Res. 240(1-2), 87-92 (2008).
39. Lucke T, Choudhry R, Thom R, Selmer IS, Burden AD, Hodgins MB. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium, and buccal epithelium. J. Invest. Dermatol. 112(3), 354-361 (1999).
40. Djalilian AR, McGaughey D, Patel S et al. Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response. J. Clin. Invest. 116(5), 1243-1253 (2006).
41. Lai-Cheong JE, Arita K, McGrath JA. Genetic diseases of junctions. J. Invest. Dermatol. 127(12), 2713-2725 (2007).
42. van Steensel MA. Gap junction diseases of the skin. Am. J. Med. Genet. C Semin. Med. Genet. 131C(1), 12-19 (2004).
43. Mazereeuw-Hautier J, Bitoun E, Chevrant- Breton J et al. Keratitis-ichthyosis- deafness syndrome: disease expression and spectrum of connexin 26 (GJB2) mutations in 14 patients. Br. J. Dermatol. 156(5), 1015-1019 (2007).
44. Conrado LA, Marques SA, Lastoria JC, Cuce LC, Marques ME, Dillon NL. Keratitis-ichthyosis-deafness (KID) syndrome with squamous cell carcinoma. Int. J. Dermatol. 46(4), 403-406 (2007).
45. Wang CM, Lincoln J, Cook JE, Becker DL. Abnormal connexin expression underlies delayed wound healing in diabetic skin. Diabetes 56(11), 2809-2817 (2007).
46. Wright CS, van Steensel MA, Hodgins MB, Martin PE. Connexin mimetic peptides improve cell migration rates of human epidermal keratinocytes and dermal fibroblasts in vitro. Wound Repair Regen. 17(2), 240-249 (2009).
47. Ghatnekar GS, O'Quinn MP, Jourdan LJ, Gurjarpadhye AA, Draughn RL, Gourdie RG. Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. Regen. Med. 4(2), 205-223 (2009).
48. Rhett JM, Ghatnekar GS, Palatinus JA, O'Quinn M, Yost MJ, Gourdie RG. Novel therapies for scar reduction and regenerative healing of skin wounds. Trends Biotechnol. 26(4), 173-180 (2008).
49. Apps SA, Rankin WA, Kurmis AP. Connexin 26 mutations in autosomal recessive deafness disorders: a review. Int. J. Audiol. 46(2), 75-81 (2007).
50. Sabag AD, Dagan O, Avraham KB. Connexins in hearing loss: a comprehensive overview. J. Basic Clin. Physiol. Pharmacol. 16(2-3), 101-116 (2005).
51. Man YK, Trolove C, Tattersall D et al. A deafness-associated mutant human connexin 26 improves the epithelial barrier in vitro. J. Membr. Biol. 218(1-3), 29-37 (2007). (Pubitemid 350132115)
52. D'Adamo P, Guerci VI, Fabretto A et al. Does epidermal thickening explain GJB2 high carrier frequency and heterozygote advantage? Eur. J. Hum. Genet. 17(3), 284-286 (2009).
53. Lee H, Lee I, Seul K, Rhee S. Growth inhibition by connexin26 expression in cultured rodent tumor cells. Mol. Cells 14(1), 136-142 (2002). (Pubitemid 41582991)
54. Wilson GN, Squires RH Jr, Weinberg AG. Keratitis, hepatitis, ichthyosis, and deafness: report and review of KID syndrome. Am. J. Med. Genet. 40(3), 255-259 (1991).
55. van Steensel MA, van Geel M, Nahuys M, Smitt JH, Steijlen PM. A novel connexin 26 mutation in a patient diagnosed with keratitis-ichthyosis- deafness syndrome. J. Invest. Dermatol. 118(4), 724-727 (2002).
56. van Geel M, van Steensel MA, Kuster W et al. HID and KID syndromes are associated with the same connexin 26 mutation. Br. J. Dermatol. 146(6), 938-942 (2002).
57. Sonoda S, Uchino E, Sonoda KH et al. Two patients with severe corneal disease in KID syndrome. Am. J. Ophthalmol. 137(1), 181-183 (2004). (Pubitemid 38045210)
58. Richard G, Rouan F, Willoughby CE et al. Missense mutations in GJB2 encoding connexin-26 cause the ectodermal dysplasia keratitis-ichthyosis- deafness syndrome. Am. J. Hum. Genet. 70(5), 1341-1348 (2002).
59. Janecke AR, Hennies HC, Gunther B et al. GJB2 mutations in keratitis-ichthyosis- deafness syndrome including its fatal form. Am. J. Med. Genet. 133(2), 128-131 (2005).
60. Arita K, Akiyama M, Aizawa T et al. A novel N14Y mutation in Connexin 26 in keratitis-ichthyosis-deafness syndrome: analyses of altered gap junctional communication and molecular structure of N terminus of mutated Connexin 26. Am. J. Pathol. 169(2), 416-423 (2006).
61. Akiyama M, Sakai K, Arita K et al. A novel GJB2 mutation p.Asn54His in a patient with palmoplantar keratoderma, sensorineural hearing loss and knuckle pads. J. Invest. Dermatol. 127(6), 1540-1543 (2007). (Pubitemid 46762973)
62. Lee JR, Derosa AM, White TW. Connexin mutations causing skin disease and deafness increase hemichannel activity and cell death when expressed in Xenopus oocytes. J. Invest. Dermatol. 129(4), 870-878 (2009).
63. Montgomery JR, White TW, Martin BL, Turner ML, Holland SM. A novel connexin 26 gene mutation associated with features of the keratitis-ichthyosis- deafness syndrome and the follicular occlusion triad. J. Am. Acad. Dermatol. 51(3), 377-382 (2004).
64. Maintz L, Betz RC, Allam JP et al. Keratitis-ichthyosis-deafness syndrome in association with follicular occlusion triad. Eur. J. Dermatol. 15(5), 347-352 (2005). (Pubitemid 41337411)
65. van Steensel MA, Steijlen PM, Bladergroen RS, Hoefsloot EH, van Ravenswaaij-Arts CM, van Geel M. A phenotype resembling the Clouston syndrome with deafness is associated with a novel missense GJB2 mutation. J. Invest. Dermatol. 123(2), 291-293 (2004).
66. Van Steensel MA, Van Geel M, Steijlen PM. Further delineation of the hypotrichosis-deafness syndrome. Eur. J. Dermatol. 15(6), 437-438 (2005).
67. Lazic T, Horii KA, Richard G, Wasserman DI, Antaya RJ. A report of GJB2 (N14K) Connexin 26 mutation in two patients - a new subtype of KID syndrome? Pediatr. Dermatol. 25(5), 535-540 (2008).
68. Richard G, White TW, Smith LE et al. Functional defects of Cx26 resulting from a heterozygous missense mutation in a family with dominant deaf-mutism and palmoplantar keratoderma. Hum. Genet. 103(4), 393-399 (1998). (Pubitemid 28542946)
69. Oshima A, Doi T, Mitsuoka K, Maeda S, Fujiyoshi Y. Roles of Met-34, Cys-64, and Arg-75 in the assembly of human connexin 26. Implication for key amino acid residues for channel formation and function. J. Biol. Chem. 278(3), 1807-1816 (2003).
70. Leonard NJ, Krol AL, Bleoo S, Somerville MJ. Sensorineural hearing loss, striate palmoplantar hyperkeratosis, and knuckle pads in a patient with a novel connexin 26 (GJB2) mutation. J. Med. Genet. 42(1), E2 (2005).
71. Heathcote K, Syrris P, Carter ND, Patton MA. A connexin 26 mutation causes a syndrome of sensorineural hearing loss and palmoplantar hyperkeratosis (OMIM 148350). J. Med. Genet. 37(1), 50-51 (2000).
72. Rouan F, White TW, Brown N et al. trans-dominant inhibition of connexin-43 by mutant connexin-26: implications for dominant connexin disorders affecting epidermal differentiation. J. Cell. Sci. 114(Pt 11), 2105-2113 (2001). (Pubitemid 32586635)
73. Richard G, Brown N, Ishida-Yamamoto A, Krol A. Expanding the phenotypic spectrum of Cx26 disorders: Bart- Pumphrey syndrome is caused by a novel missense mutation in GJB2. J. Invest. Dermatol. 123(5), 856-863 (2004).
74. Alexandrino F, Sartorato EL, Marques-de- Faria AP, Steiner CE. G59S mutation in the GJB2 (connexin 26) gene in a patient with Bart-Pumphrey syndrome. Am. J. Med. Genet. A 136(3), 282-284 (2005).
75. Maestrini E, Korge BP, Ocana-Sierra J et al. A missense mutation in connexin 26, D66H, causes mutilating keratoderma with sensorineural deafness (Vohwinkel's syndrome) in three unrelated families. Hum. Mol. Genet. 8(7), 1237-1243 (1999). (Pubitemid 29328992)
76. Solis RR, Diven DG, Trizna Z. Vohwinkel's syndrome in three generations. J. Am. Acad. Dermatol. 44(2 Suppl.), 376-378 (2001).
77. Snoeckx RL, Hassan DM, Kamal NM, Van Den Bogaert K, Van Camp G. Mutation analysis of the GJB2 (connexin 26) gene in Egypt. Hum. Mutat. 26(1), 60-61 (2005).
78. Bakirtzis G, Choudhry R, Aasen T et al. Targeted epidermal expression of mutant Connexin 26(D66H) mimics true Vohwinkel syndrome and provides a model for the pathogenesis of dominant connexin disorders. Hum. Mol. Genet. 12(14), 1737-1744 (2003). (Pubitemid 36896665)
79. de Zwart-Storm EA, Hamm H, Stoevesandt J et al. A novel missense mutation in GJB2 disturbs gap junction protein transport and causes focal palmoplantar keratoderma with deafness. J. Med. Genet. 45(3), 161-166 (2008).
80. Piazza V, Beltramello M, Menniti M et al. Functional analysis of R75Q mutation in the gene coding for Connexin 26 identified in a family with nonsyndromic hearing loss. Clin. Genet. 68(2), 161-166 (2005).
81. Iossa S, Chinetti V, Auletta G et al. New evidence for the correlation of the p.G130V mutation in the GJB2 gene and syndromic hearing loss with palmoplantar keratoderma. Am. J. Med. Genet. A 149A(4), 685-688 (2009).
82. Brown CW, Levy ML, Flaitz CM et al. A novel GJB2 (connexin 26) mutation, F142L, in a patient with unusual mucocutaneous findings and deafness. J. Invest. Dermatol. 121(5), 1221-1223 (2003).
83. Schnichels M, Worsdorfer P, Dobrowolski R et al. The connexin31 F137L mutant mouse as a model for the human skin disease erythrokeratodermia variabilis (EKV). Hum. Mol. Genet. 16(10), 1216-1224 (2007). (Pubitemid 47062717)
84. Qiu C, Coutinho P, Frank S et al. Targeting connexin43 expression accelerates the rate of wound repair. Curr. Biol. 13(19), 1697-1703 (2003).
85. Mendes da Costa S. Erythro-et keratodermia variabilis in a mother and a daughter. Acta Derm. Venerol. 1925(6), 255-261.
86. Richard G, Smith LE, Bailey RA et al. Mutations in the human connexin gene GJB3 cause erythrokeratodermia variabilis. Nat. Genet. 20(4), 366-369 (1998).
87. Macari F, Landau M, Cousin P et al. Mutation in the gene for connexin 30.3 in a family with erythrokeratodermia variabilis. Am. J. Hum. Genet. 67(5), 1296-1301 (2000). (Pubitemid 30816332)
88. Richard G, Brown N, Rouan F et al. Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations. J. Invest. Dermatol. 120(4), 601-609 (2003). (Pubitemid 36344003)
89. Renner R, Paasch U, Simon JC, Froste UG, Heinritz W. A new mutation in the GJB3 gene in a patient with erythrokeratodermia variabilis. J. Eur. Acad. Dermatol. Venereol. 22(6), 750-751 (2008).
90. van Steensel MA, Oranje AP, van der Schroeff JG, Wagner A, van Geel M. The missense mutation G12D in connexin30.3 can cause both erythrokeratodermia variabilis of Mendes da Costa and progressive symmetric erythrokeratodermia of Gottron. Am. J. Med. Genet. A 149A(4), 657-661 (2009).
91. Macfarlane AW, Chapman SJ, Verbov JL. Is erythrokeratoderma one disorder? A clinical and ultrastructural study of two siblings. Br. J. Dermatol. 124(5), 487-491 (1991).
92. Stander S, Stadelmann A, Traub O, Traupe H, Metze D. [Erythrokeratodermia variabilis (EKV) - a disorder due to altered epidermal expression of gap junction proteins]. J. Dtsch Dermatol. Ges. 3(5), 354-358 (2005).
93. Gottfried I, Landau M, Glaser F et al. A mutation in GJB3 is associated with recessive erythrokeratodermia variabilis (EKV) and leads to defective trafficking of the connexin 31 protein. Hum. Mol. Genet. 11(11), 1311-1316 (2002). (Pubitemid 34555528)
94. van Steensel MA, van Geel M. Does recessive EKV exist? J. Invest. Dermatol. 124(1), 268-269 (2005).
95. Plantard L, Huber M, Macari F, Meda P, Hohl D. Molecular interaction of connexin 30.3 and connexin 31 suggests a dominant-negative mechanism associated with erythrokeratodermia variabilis. Hum. Mol. Genet. 12(24), 3287-3294 (2003). (Pubitemid 37541074)
96. van Geel M, van Steensel MA, Steijlen PM. Connexin 30.3 (GJB4) is not required for normal skin function in humans. Br. J. Dermatol. 147(6), 1275-1277 (2002).
97. Arita K, Akiyama M, Tsuji Y, Onozuka T, Shimizu H. Erythrokeratoderma variabilis without connexin 31 or connexin 30.3 gene mutation: immunohistological, ultrastructural and genetic studies. Acta Derm. Venereol. 83(4), 266-270 (2003). (Pubitemid 36920600)
98. Common JE, O'Toole EA, Leigh IM et al. Clinical and genetic heterogeneity of erythrokeratoderma variabilis. J. Invest. Dermatol. 125(5), 920-927 (2005).
99. Matsumoto K, Muto M, Seki S et al. Loricrin keratoderma: a cause of congenital ichthyosiform erythroderma and collodion baby. Br. J. Dermatol. 145(4), 657-660 (2001). (Pubitemid 33754931)
100. Cama E, Melchionda S, Palladino T et al. Hearing loss features in GJB2 biallelic mutations and GJB2/GJB6 digenic inheritance in a large Italian cohort. Int. J. Audiol. 48(1), 12-17 (2009).
101. Common JE, Becker D, Di WL, Leigh IM, O'Toole EA, Kelsell DP. Functional studies of human skin disease- and deafnessassociated connexin 30 mutations. Biochem. Biophys. Res. Commun. 298(5), 651-656 (2002). (Pubitemid 35356790)
102. van Steensel MA, Jonkman MF, van Geel M, Steijlen PM, McLean WH, Smith FJ. Clouston syndrome can mimic pachyonychia congenita. J. Invest. Dermatol. 121(5), 1035-1038 (2003).
103. Jan AY, Amin S, Ratajczak P, Richard G, Sybert VP. Genetic heterogeneity of KID syndrome: identification of a Cx30 gene (GJB6) mutation in a patient with KID syndrome and congenital atrichia. J. Invest. Dermatol. 122(5), 1108-1113 (2004). (Pubitemid 38651083)
104. Essenfelder GM, Bruzzone R, Lamartine J et al. Connexin30 mutations responsible for hidrotic ectodermal dysplasia cause abnormal hemichannel activity. Hum. Mol. Genet. 13(16), 1703-1714 (2004). (Pubitemid 39173440)
105. Lemaitre G, Sivan V, Lamartine J et al. Connexin 30, a new marker of hyperproliferative epidermis. Br. J. Dermatol. 155(4), 844-846 (2006). (Pubitemid 44352574)
106. Nemoto-Hasebe I, Akiyama M, Kudo S et al. Novel mutation p.Gly59Arg in GJB6 encoding connexin 30 underlies palmoplantar keratoderma with pseudoainhum, knuckle pads and hearing loss. Br. J. Dermatol. 161(2), 452-455 (2009).
107. Paznekas WA, Karczeski B, Vermeer S et al. GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Hum. Mutat. 30(5), 724-733 (2009).
108. Vreeburg M, de Zwart-Storm EA, Schouten MI et al. Skin changes in oculo-dento-digital dysplasia are correlated with C-terminal truncations of connexin 43. Am. J. Med. Genet. A 143(4), 360-363 (2007). (Pubitemid 46214199)
109. van Steensel MA, Spruijt L, van der Burgt I et al. A 2-bp deletion in the GJA1 gene is associated with oculo-dento-digital dysplasia with palmoplantar keratoderma. Am. J. Med. Genet. A 132(2), 171-174 (2005). (Pubitemid 40093326)
110. Gillespie FD. A hereditary syndrome: dysplasia oculodentodigitalis. Arch. Ophthalmol. 71, 187-192 (1964).
111. Loddenkemper T, Grote K, Evers S, Oelerich M, Stogbauer F. Neurological manifestations of the oculodentodigital dysplasia syndrome. J. Neurol. 249(5), 584-595 (2002). (Pubitemid 34507833)
112. Uhlenberg B, Schuelke M, Ruschendorf F et al. Mutations in the gene encoding gap junction protein α 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am. J. Hum. Genet. 75(2), 251-260 (2004). (Pubitemid 38943868)
113. Law LY, Lin JS, Becker DL, Green CR. Knockdown of connexin 43-mediated regulation of the zone of polarizing activity in the developing chick limb leads to digit truncation. Dev. Growth Differ. 44(6), 537-547 (2002).
114. McGonnell IM, Green CR, Tickle C, Becker DL. Connexin 43 gap junction protein plays an essential role in morphogenesis of the embryonic chick face. Dev. Dyn. 222(3), 420-438 (2001). (Pubitemid 33042141)
115. Maass K, Ghanem A, Kim JS et al. Defective epidermal barrier in neonatal mice lacking the C-terminal region of connexin43. Mol. Biol. Cell. 15(10), 4597-4608 (2004). (Pubitemid 39299107)
116. Gong XQ, Shao Q, Lounsbury CS, Bai D, Laird DW. Functional characterization of a GJA1 frameshift mutation causing oculodentodigital dysplasia and palmoplantar keratoderma. J. Biol. Chem. 281(42), 31801-31811 (2006). (Pubitemid 46041445)
117. Mori R, Power KT, Wang CM, Martin P, Becker DL. Acute downregulation of connexin 43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J. Cell. Sci. 119(Pt 24), 5193-5203 (2006). (Pubitemid 46085197)
118. Thomas T, Shao Q, Laird DW. Differentiation of organotypic epidermis in the presence of skin disease-linked dominant-negative Cx26 Mutants and knockdown Cx26. J. Membr. Biol. 217(1-3), 93-104 (2007). (Pubitemid 350160004)
119. Kandyba EE, Hodgins MB, Martin PE. A murine living skin equivalent amenable to live-cell imaging: analysis of the roles of connexins in the epidermis. J. Invest. Dermatol. 128(4), 1039-1049 (2008).
120. Richard G, Brown N, Smith LE et al. The spectrum of mutations in erythrokeratodermias - novel and de novo mutations in GJB3. Hum. Genet. 106(3), 321-329 (2000). (Pubitemid 30201281)
121. Feldmeyer L, Plantard L, Mevorah B, Huber M, Hohl D. Novel mutation of connexin 31 causing erythrokeratoderma variabilis. Br. J. Dermatol. 152(5), 1072-1074 (2005). (Pubitemid 40704962)
122. Terrinoni A, Leta A, Pedicelli C et al. A novel recessive connexin 31 (GJB3) mutation in a case of erythrokeratodermia variabilis. J. Invest. Dermatol. 122(3), 837-839 (2004). (Pubitemid 38476964)
123. Wilgoss A, Leigh IM, Barnes MR et al. Identification of a novel mutation R42P in the gap junction protein β-3 associated with autosomal dominant erythrokeratoderma variabilis. J. Invest. Dermatol. 113(6), 1119-1122 (1999). (Pubitemid 30013362)